Types of Intracellular Bacteria in Atherosclerotic Plaques and Analysis of Risk Factors
Launched by TANG-DU HOSPITAL · Apr 11, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called iBacAP, is looking into the types of bacteria found inside the carotid plaques of patients with a condition known as atherosclerosis, which can narrow the arteries in the neck. The researchers want to understand what types of bacteria are present in these plaques and if certain types are linked to worse health outcomes for patients. They will study patients with various levels of artery narrowing and examine whether the specific bacteria they have affects their overall health and recovery.
To participate in this trial, individuals must have been diagnosed with significant narrowing of the carotid arteries and have experienced related health events, like a stroke or a mini-stroke. Participants will not receive any new treatments or interventions but will continue with their usual care. The study aims to include both men and women aged between 65 and 74. It’s important to note that people with certain health conditions, such as severe respiratory diseases or advanced cancers, and those who are pregnant or currently involved in other clinical studies, will not be eligible to join.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • All enrolled patients were diagnosed with clear head and neck artery stenosis and a risk event after head and neck revascularization;
- • Location of lesion: origin of internal carotid artery, bifurcation of internal and external carotid arteries;
- • Patients with symptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, and with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 50% found on angiography;
- • Asymptomatic head and neck artery stenosis and risk events after head and neck revascularization, with a degree of stenosis ≥ 70% on non-invasive examination or stenosis ≥ 60% found on angiography;
- • Asymptomatic head and neck artery stenosis and dangerous events after head and neck blood flow reconstruction, with a non-invasive examination of stenosis degree less than 70%, but angiography or other examinations indicate that the stenosis lesion is in an unstable state;
- • Symptomatic head and neck artery stenosis and risk events after head and neck revascularization, non-invasive examination of head and neck artery stenosis and risk event degree after head and neck revascularization at 50% to 69%
- Exclusion Criteria:
- • Patients with poor overall condition and intolerance to general anesthesia;
- • Patients with mental illness or severe mental illness;
- • Severe respiratory system diseases;
- • Pregnant and lactating women;
- • Participating in another clinical study;
- • Patients with advanced tumors or those who are expected to die within one year;
About Tang Du Hospital
Tang-Du Hospital, affiliated with the Fourth Military Medical University, is a leading medical institution in China renowned for its comprehensive healthcare services and advanced research capabilities. As a prominent clinical trial sponsor, Tang-Du Hospital is committed to advancing medical science through rigorous clinical research. The hospital leverages its state-of-the-art facilities and a multidisciplinary team of experts to conduct innovative studies that aim to improve patient outcomes and contribute to the global medical community. With a strong emphasis on ethical standards and patient safety, Tang-Du Hospital is dedicated to fostering collaborations that enhance the development of new therapies and medical technologies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xian, Shanxi, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported